Commission Implementing Directive 2011/56/EU of 27 April 2011 amending Council Directive 91/414/EEC to include cyproconazole as active substance and amending Commission Decision 2008/934/EC Text with EEA relevance
Annex 1ANNEX
In force · version of Jun 1, 2011
The following entry shall be added at the end of the table in Annex I to Directive 91/414/EEC:
No Common name, identification numbers IUPAC name Purity ( 1 ) Entry into force Expiration of inclusion Specific provisions ‘358 Cyproconazole CAS No: 94361-06-5 CIPAC No: 600 (2 RS ,3 RS ;2 RS ,3 SR )-2-(4-chlorophenyl)-3-cyclopropyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol ≥ 940 g/kg 1 June 2011 31 May 2021 PART A Only uses as fungicide may be authorised. PART B For the implementation of the uniform principles of Annex VI, the conclusions of the review report on cyproconazole, and in particular Appendices I and II thereof, as finalised in the Standing Committee on the Food Chain and Animal Health on 11 March 2011 shall be taken into account. In this overall assessment Member States shall pay particular attention to: (a) the dietary exposure of consumers to the residues of triazole derivative metabolites (TDMs); (b) the risk to aquatic organisms. Conditions of use shall include risk mitigation measures, where appropriate. The Member States concerned shall request the submission of confirmatory information as regards: (a) the toxicological relevance of the impurities in the technical specification; (b) analytical methods for the monitoring of cyproconazole in soil, body fluids and tissues; (c) residues of triazole derivative metabolites (TDMs) in primary crops, rotational crops and products of animal origin; (d) the long-term risk to herbivorous mammals; (e) the possible environmental impact of the preferential degradation and/or conversion of the mixture of isomers. The Member States concerned shall ensure that the applicant submits to the Commission the information set out in point (a) by 1 December 2011, the information set out in points (b), (c) and (d) by 31 May 2013 and the information set out in point (e) within two years after the adoption of specific guidance.’